Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests

被引:24
作者
Barry, AL
Fuchs, PC
Brown, SD
机构
[1] Clinical Microbiology Institute, Tualatin, OR 97062
关键词
D O I
10.1093/jac/39.suppl_1.87
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
For testing bacterial susceptibility to the streptogramin quinupristin/dalfopristin, it seems reasonable that the test reagent should contain a similar ratio of the two compounds as in the therapeutic material, i.e. 30% quinupristin and 70% dalfopristin. The precise ratio of quinupristin to dalfopristin is not critical as long as threshold concentrations of both drugs are present. In-vitro tests were not altered by minor changes in pH, incubation in CO2 or by addition of lysed horse blood to the medium. Filter paper discs containing 15 mu g of the quinupristin/dalfopristin reagent are preferred for agar diffusion susceptibility testing in order to optimize disc tests with enterococci. Provisional interpretive criteria for pathogens not requiring blood or increased COP are: susceptible, inhibition zone diameters of greater than or equal to 19 mm or MIC less than or equal to 1.0 mgiL; intermediate, 16-18 mm or MIC 2.0 mg/L; resistant, less than or equal to 15 mm or MIC greater than or equal to 4.0 mg/L. Those criteria will need to be reassessed as clinical experiences become available. Of particular concern is the role of quinupristin/dalfopristin in the treatment of infections due to Haemophilus influenzae or Enterococcus faecalis: the clinically relevant interpretive category for each of those two species is yet to be determined.
引用
收藏
页码:87 / 92
页数:6
相关论文
共 14 条
  • [1] RP-59500, A NEW STREPTOGRAMIN HIGHLY-ACTIVE AGAINST RECENT ISOLATES OF NORTH-AMERICAN STAPHYLOCOCCI
    ARCHER, GL
    AUGER, P
    DOERN, GV
    FERRARO, MJ
    FUCHS, PC
    JORGENSEN, JH
    LOW, DE
    MURRAY, PR
    RELLER, LB
    STRATTON, CW
    WENNERSTEN, CB
    MOELLERING, RC
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1993, 16 (03) : 223 - 226
  • [2] IN-VITRO ACTIVITIES OF A STREPTOGRAMIN (RP59500), 3 MACROLIDES, AND AN AZALIDE AGAINST 4 RESPIRATORY-TRACT PATHOGENS
    BARRY, AL
    FUCHS, PC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (01) : 238 - 240
  • [3] INVITRO AND INVIVO SYNERGIC ACTIVITY AND FRACTIONAL INHIBITORY CONCENTRATION (FIC) OF THE COMPONENTS OF A SEMISYNTHETIC STREPTOGRAMIN, RP 59500
    BOUANCHAUD, DH
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 : 95 - 99
  • [4] CARMICAN MG, 1996, DIAGNOSTIC MICROBIOL, V24, P59
  • [5] FASS RJ, 1991, ANTIMICROBIAL AGENTS, V35, P533
  • [6] IN-VITRO ACTIVITY OF RP-59500 (QUINUPRISTIN DALFOPRISTIN) AGAINST ANTIBIOTIC-RESISTANT STRAINS OF STREPTOCOCCUS-PNEUMONIAE AND ENTEROCOCCI
    JOHNSON, CC
    SLAVOSKI, L
    SCHWARTZ, M
    MAY, P
    PITSAKIS, PG
    SHUR, AL
    LEVISON, ME
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (03) : 169 - 173
  • [7] EMERGING MULTIPLY RESISTANT ENTEROCOCCI AMONG CLINICAL ISOLATES .1. PREVALENCE DATA FROM 97 MEDICAL-CENTER SURVEILLANCE STUDY IN THE UNITED-STATES
    JONES, RN
    SADER, HS
    ERWIN, ME
    ANDERSON, SC
    ALDRIDGE, KA
    ALLEN, S
    ANHALT, J
    APPELBAUM, P
    ARRINGTON, KL
    AYERS, L
    BAKER, C
    BEAVIS, K
    BERGER, J
    BERTHOLD, G
    BIRNBAUM, M
    BOYLE, J
    BRECHER, S
    BRECKENRIDGE, R
    BROWN, W
    BRUCKNER, D
    CARROLL, K
    CHAUDHARY, S
    CLEARY, T
    COCKERILL, F
    COYLE, M
    CRAWFORD, V
    DALTON, H
    DOERN, G
    EDBERG, S
    GELFAND, M
    GERLACH, EH
    GOODMAN, N
    GORZYNSKI, E
    GREEN, P
    GROSCHEL, D
    HANFF, P
    HANNA, B
    HARRELL, L
    HAUGEN, T
    HEAGREY, M
    HUMPHRIES, J
    ISENBERG, H
    JENKINS, S
    JONES, E
    JORGENSEN, J
    KAUFFMAN, C
    KEISER, J
    KOCKA, F
    KOMINOS, S
    LEVISON, M
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (02) : 85 - 93
  • [8] JORGENSEN JH, 1995, 35 INT C ANT AG CHEM, P107
  • [9] Quinupristin/dalfopristin: Spectrum of activity, pharmacokinetics, and initial clinical experience
    Low, DE
    [J]. MICROBIAL DRUG RESISTANCE, 1995, 1 (03) : 223 - 234
  • [10] *NAT COMM CLIN LAB, 1993, M2A5 NAT COMM CLIN L